BZO-CHMOXIZID (CHM-MDA-19) is a synthetic cannabinoid compound first reported in 2008 in the same series as the better known derivative MDA-19.
It started to be widely sold as an ingredient in grey-market synthetic cannabis blends in 2021 following the introduction of legislation in China which for the first time introduced general controls on various classes of synthetic cannabinoids, but did not include the group to which MDA-19 and BZO-CHMOXIZID belong.
Synthetic cannabinoids have been reported to cause psychoactive effects similar to delta-9-tetrahydrocannabinol (THC). Synthetic cannabinoids have caused adverse events, including deaths.
Closely related analogue BZO-HEXOXIZID (MDA 19) was synthesized and studied in the late 2000’s by scientists at the University of Texas M. D. Anderson Cancer Center.